NANOFORM FINLAND OYJ |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.24 EUR | +3.94% |
|
-16.26% | +41.32% |
| 04-11 | Nanoform Finland to Deliver Nanomedicine Technology to Japan | MT |
| 04-11 | Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan | CI |
| Sales 2024 * | 7.48M 8.02M 641M | Sales 2025 * | 14.6M 15.64M 1.25B | Capitalization | 184M 197M 15.76B |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -16.07M -1.28B | Net income 2025 * | -11M -11.78M -941M | EV / Sales 2024 * | 20.5 x |
| Net cash position 2024 * | 31M 33.21M 2.65B | Net cash position 2025 * | 21.34M 22.85M 1.83B | EV / Sales 2025 * | 11.2 x |
| P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-15.4
x | Employees | 165 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nanoform Finland Oyj
More press releases
| 1 day | +3.94% | ||
| 1 week | -16.26% | ||
| Current month | -17.34% | ||
| 1 month | -15.63% | ||
| 3 months | -14.50% | ||
| 6 months | +41.77% | ||
| Current year | +41.32% |
1 week
2.00
2.71
1 month
2.002.79
Current year
1.553.50
1 year
1.473.50
3 years
1.478.71
5 years
1.478.80
10 years
1.478.80
| Managers | Title | Age | Since |
|---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 31/12/14 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 31/12/14 |
| Investor Relations Contact | - | 30/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 68 | 01/04/19 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 31/12/18 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 31/12/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 2.24 | +3.94% | 115 |
| 26/04/24 | 2.155 | +6.16% | 194,697 |
| 25/04/24 | 2.03 | -21.77% | 493,841 |
| 24/04/24 | 2.595 | -0.76% | 4,907 |
| 23/04/24 | 2.615 | -2.24% | 7,154 |
Delayed Quote Nasdaq Helsinki, April 29, 2024 at 08:01 am
More quotes
Nanoform Finland Oyj is a Finland-based company that operates in the global pharmaceutical industry. The Company is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyjâs business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Groupâs strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
Calendar
20/05/2024
- Global DDF Summit
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.155
EUR
Average target price
4.4
EUR
Spread / Average Target
+104.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.32% | 197M | |
| +1.51% | 42.75B | |
| +48.54% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- NANOFH Stock
